← FDA DRUG APPROVALS

FDA ANDA · ANDA207479

BUPROPION HYDROCHLORIDE (XL)

bupropion hydrochloride

Sponsor: SCIEGEN PHARMS

APPLICATION
ANDA207479
TYPE
ANDA
ORIGINAL APPROVAL
2017-04-12
LATEST ACTION
2020-06-30
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

BUPROPION HYDROCHLORIDEPrescription
BUPROPION HYDROCHLORIDE 300MG · TABLET, EXTENDED RELEASE · ORAL
BUPROPION HYDROCHLORIDEPrescription
BUPROPION HYDROCHLORIDE 150MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2020-06-30Labeling · Supplement 2 · standardAP
2020-06-30Labeling · Supplement 10 · standardAP
2017-04-12UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →